Exclusive: ADC startup Mythic recruits Jazz exec to lead company; Dyne’s CEO shuffle

Mythic Therapeutics has gone more than a year and a half without a CEO.

That’s changing on April 1, as George Eliades will join the Waltham, MA-based antibody-drug conjugate biotech. Eliades is coming from Jazz Pharmaceuticals, where he’s served as senior vice president of corporate development and chief transformation officer for the past three and a half years.

In the interim, Mythic’s CEO duties were shared among chief scientist Brian Fiske, COO Sandra Poole and chief development officer Gilles Gallant, according to a press release.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。